Conduit Pharmaceuticals announces novel cocrystal patent filing for VTAMA

Conduit Pharmaceuticals (CDT) announces the filing of two groundbreaking patents for tapinarof, VTAMA, including a dual active cocrystal, pairing the drug currently approved in the US for psoriasis and atopic dermatitis with a complementary drug substance known to address key patient needs in inflammatory skin conditions. The Company anticipates this combination drug approach could offer enhanced patient benefits over existing tapinarof formulations by addressing both therapeutic needs and known side effects, such as pain and itch, which are a known priority to sufferers of these conditions but typically overlooked by standard treatments that focus on the underlying disease alone.